SARS-CoV-2 Omicron BA.5 infection recurrence after Paxlovid treatment: The first case report in Hunan Province. / 湖南省首例Paxlovidæ²»ç–—æ–°åž‹å† çŠ¶ç— æ¯’å¥¥å¯†å ‹æˆŽBA.5å˜å¼‚æ ªå¤é˜³ç— ä¾‹æŠ¥é“.

ABSTRACT

We report a case of coronavirus disease 2019 (COVID-19) patient who was cured by oral administration of nirmatrelvir/ritonavir (Paxlovid). The patient was treated with Paxlovid after being first infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 variant. On the 11th day after SARS-CoV-2 nucleic acid test turned negative, SARS-CoV-2 nucleic acid test was positive again, and the threshold of nucleic acid cycle number was equivalent to that of the first infection. The results of two whole gene sequencing showed that it was the same virus strain infection, suggesting that the case was re-positive. Without specific treatment, SARS-CoV-2 nucleic acid detection in nasopharyngeal swab turned negative. It is not uncommon for Paxlovid to recover after treating COVID-19, and most of the patients can recover without specific treatment. However, it is necessary to further study the mechanism that may lead to the recovery of SARS-CoV-2.